Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 0.55 |
| ▸ | MYC | P01106 | 2/20 | 0.54 |
| ▸ | MAX | P61244 | 2/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | EP300 | Q09472 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28316244 | 0.89 | HCAR3 (0.59) | HCAR3CASP6TSHRXDHTTR | |
| SCHEMBL528040 | 0.86 | EP300 (0.61) | HCAR3MYCMAXCASP6TSHR | |
| SCHEMBL30658490 | 0.86 | EP300 (0.61) | HCAR3MYCMAXCASP6TSHR | |
| SCHEMBL8072162 | 0.81 | CA12 (0.51) | CASP6TSHRALDH1A1GAATTR | |
| SCHEMBL31003858 | 0.80 | CASP6 (0.63) | HCAR3MYCMAXCASP6TSHR | |
| SCHEMBL16974724 | 0.80 | CASP6 (0.63) | HCAR3MYCMAXCASP6TSHR | |
| SCHEMBL3537490 | 0.80 | MAPT (0.62) | HCAR3MYCMAXCASP6TSHR | |
| SCHEMBL527704 | 0.80 | MYC (0.78) | HCAR3MYCMAXCASP6TSHR | |
| Hydrochloric Acid SCHEMBL3729179 | 0.79 | MAPT (0.60) | HCAR3MYCMAXCASP6TSHR | |
| SCHEMBL223878 | 0.78 | TTR (0.64) | HCAR3MYCMAXCASP6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9217022-B2 | GLP-1 receptor agonist compounds having stabilized regions | ASTRAZENECA PHARMACEUTICALS LP (US) | 2015-12-22 | — | — | US | disclosed |
| US-9217022-B2 | GLP-1 receptor agonist compounds having stabilized regions | ASTRAZENECA PHARMACEUTICALS LP (US) | 2015-12-22 | — | — | US | disclosed |
| US-9217022-B2 | GLP-1 receptor agonist compounds having stabilized regions | ASTRAZENECA PHARMACEUTICALS LP (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2598161-A2 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | Amylin Pharmaceuticals, LLC (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015975-A2 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015975-A2 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | GLP1R, GIPR, GCGR | HCAR3 386/4885MYC 3191/4885MAX 519/4885 |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | HCAR3 3942/4885MYC 4608/4885MAX 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.